Laura Spring, MD

Laura Spring, MD Massachusetts General Hospital Localized breast cancer patients with higher risk disease are often treated with chemotherapy in the neoadjuvant (before surgery) setting. However, it is difficult to predict how breast cancer will respond to treatment given in the neoadjuvant setting and we currently lack any specific blood tests to help answer [...]

Laura Spring, MD2019-01-20T21:37:12-05:00

Jing Hu, PhD

Jing Hu, PhD Memorial Sloan Kettering Cancer Center Metastasis is a major clinical hurdle in breast cancer treatment, with poor prognosis (5-year survival around 26.5%). Despite surgical resection of the primary tumor and systemic therapy to suppress residual disease, distant metastatic relapse may still occur within a few months to years, implying the existence [...]

Jing Hu, PhD2019-01-20T21:36:34-05:00

Veerle Daniels, PhD

Veerle Daniels, PhD Dana-Farber Cancer Institute Despite recent advances in treatment options, breast cancer remains the second leading cause of cancer-related deaths in women. Triple negative breast cancer (TNBC) is a subgroup of breast cancer that is characterized by the absence of the estrogen receptor, the progesterone receptor and HER2-amplification. Because of the lack of [...]

Veerle Daniels, PhD2019-01-20T21:35:56-05:00

Ana Garrido-Castro, MD

Ana Garrido-Castro, MD Dana-Farber Cancer Institute Choosing the best treatments for metastatic breast cancer depends increasingly on molecular features, such as tumor subtype. Patients with hormone receptor-positive/HER2-negative breast cancer are typically treated initially with hormonal therapies, and then subsequently with chemotherapy once hormonal therapy loses its effectiveness. Loss of hormone receptor expression has been described as [...]

Ana Garrido-Castro, MD2019-07-03T09:44:15-05:00